BioXcel Therapeutics, Inc.
https://www.bioxceltherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioXcel Therapeutics, Inc.
Otsuka Counts The Cost Of Alzheimer’s Agitation Fail
The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.
Finance Watch: Impel’s Cash Has Nearly Run Out Despite Commercial Push
Restructuring Edition: Impel eliminated R&D spending earlier this year to focus on Trudhesa commercialization, but is examining all options, including bankruptcy, as its funding runs out. Also, Alaunos, BioXcel and others announce job cuts and strategic shifts during second quarter updates.
Data Integrity Questions Cast Pall On Alzheimer’s Agitation Data For BioXcel’s Igalmi
The company reported positive efficacy results, but also revealed allegations that an investigator had failed to adhere to trial protocol and was alleged to have fabricated emails to cover their tracks.
Part One Disappointment For BioXcel’s Igalmi In Pivotal Agitation Trial
The US firm’s drug for schizophrenia- and bipolar-related agitation Igalmi has failed part one of a pivotal trial in at-home patients, but the option for higher dosing in part two combined with placebo-like safety could offer hope.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice